The affinity of ristocetin B for analogues of the C-terminal tripeptide sequence of bacterial cell wall mucopeptide precursors resembles that of vancomycin. Complexformation requires a D-configuration in the two amino acid residues of the Cterminal dipeptide, an L-configuration is preferred in the preceding amino acid residue and positive charges on the peptide molecule decrease its affinity. The specificity of ristocetin B, however, differs from that of vancomycin in the requirements for the size of the side chains on the C-terminal dipeptide. These differences may explain the observed differences in antibiotic behaviour of vancomycin and ristocetin with particular micro-organisms. The optical rotatory dispersion andu.v.-absorption characteristics of the ristocetins are very different from those of vancomycin but nearly identical with those of ristomycin A. Aglycones prepared from ristomycin A were antibiotically active and also combined with a specific peptide.
The ristocetins are antibiotics isolated from culture media of Nocardia lurida N.R.R.L 2430 (Grundy et al. 1957) , and whose mechanism of action is probably identical with that of vancomycin (Reynolds, 1966) . Perkins (1969) added further support to this idea by showing that ristocetins A and B, like vancomycin, formed specific complexes with mucopeptide precursors or simple alanine peptides. All these peptides terminated in D-Ala-D-Ala. The purpose of the work described in this paper is to examine the specificity of ristocetin B for peptides in which alterations to the side chains of these and other residues have been introduced. A comparison between the specificities of ristocetin B and vancomycin (Nieto & Perkins, 1971b ) is used in an attempt to explain differences in the inhibition pattern of both antibiotics, such as the ones found by Sinha & Neuhaus (1968) .
MATERTATLS AN]) METHODS
Chemical8. The preparation of all the peptides utilized in this work has been previously described Perkins, 1971b) . Ristocetins A and B were kindly given by Abbott Laboratories, N. Chicago, Ill., U.S.A., and ristomycin A by Prof G. F. Gause. The specific extinction ofristocetin B, corrected for loss of weight (11%) and ash (0.4%), was El% = 49.0±1 at 280nm.
Ri8tomycin aglycone. This was prepared from ristomycin A by methanolysis in 1 M-HCl (reflux, 1 h) as described by Lomakina, Muravyeva & Puskas (1968b) , except that it was precipitated from solution at pH9 by the addition of 20 volumes of acetone. The product was washed with acetone and purified by silica-gel t.l.c. in nbutanol-acetic acid-water (3:1:1, by vol) . The diazosulphanilic acid reagent (Ames & Mitchell, 1952) A8aociation constants. Binding of peptides was measured by u.v. difference spectroscopy and association constants were deduced from Scatchard plots of the binding results as described by Nieto & Perkins (1971a) . A very dilute solution of the antibiotic (35. 4,ug/ml) Nieto & Perkins (1971a) .
RESULTS
To facilitate the description of the results the positions of amino acid residues within sequences are numbered in the order: H-3-2-1-OH. The sequence L-Lys-D-Ala-D-Ala is used as a standard for comparison of the effect of alterations in amino acid residues on the affinity for antibiotic. The molecular weight chosen for ristocetin, based on peptide titrations similar to those reported for vancomycin (Nieto & Perkins, 1971a) , was 1800, for which value a Scatchard plot gave 0.98 combining sites per mol.
Specificity characteri?tic8 of ri8tocetin B. (Nieto & Perkins, 1971b) the terminal residue to a glycine resulted in a larger decrease in affinity for ristocetin B than in affinity for vancomycin. Thus it seems that the steric restrictions for binding imposed at position 1 of the peptide by ristocetin are less exact than those imposed by vancomycin. Furthermore, for ristocetin the optimlum size for side chains in the Dconfiguration may be bigger than a methyl group. However, the charge at position 1 seems to be more critical for ristocetin B than for vancomycin. The peptide Ac2-L-Lys-D-Ala-D-Lys (peptide 4) with a positively charged side chain in residue 1, combined better than Ac2-L-Lys-D-Ala-D-Leu (peptide 3) with vancomycin but less well with ristocetin B. Thus there is presumably an electrostatic restriction at position 1 in the case of ristocetin B that is absent in the case of vancomycin. This might be related to the presence of an extra amino group per molecule of ristocetin as compared with vancomycin (Lomakina, Muravyeva & Yurina, 1970a; Nieto & Perkins, 1971a) .
Variatons in the 8ide chain of re8idue 2. A different situation was found in the case ofthis residue. Increasing the size of the D-side chain from a methyl group (peptide 1) to an isobutyl group (peptide 9) decreased the affity for vancomycin fivefold and for ristocetin B tenfold. Conversely, decreasing the size of the side chain from a methyl to a hydrogen (peptides 1 and 8) produced a fairly large decrease in the affinity of the peptide for vancomycin but only a minor one in the case of ristocetin B. Thus ristocetin B seems to be sterically more restrictive than vancomycin at residue 2. Given the specificity shown by ristocetin B at residues 1 and 2 it is not surprising that Ac-L-Ala-D-Glu-Gly (peptide 21), a peptide with high affinity for vancomycin, combined very poorly with ristocetin B. The low affinity may also have been attributable to a charge effect. The relative affinities of other peptides in which simultaneous alterations in positions 1, 2 and 3 have been introduced (Table 1) could also have been approximately predicted from the specificity shown at positions 1 and 2. Interactions contributing to the ob8erved free enthaipy change8. Table 2 shows the contributions to the free enthalpy of combination made by different portions of the peptide molecule. The values for the so-called partial AG have been obtained by comparing overall values for peptides differing only in one side chain, taking as reference the corresponding peptide with a hydrogen atom in the position concerned (a glycine residue). With ristocetin B, as with vancomycin, it is clear that the peptide 'backbone' contributes about half of the free enthalpy of the binding, the rest of the contribution being made by the side chains. For both antibiotics these contributions of the side chains are not additive and hence not independent of each other. The presence or absence of other side chains as well as the overall length of the peptide determines to a large extent the contribution made to the binding by a particular side chain. Nevertheless, marked differences were observed in the contribution to the free enthalpies of binding by side chains in positions 1 and 2, depending on whether vancomycin or ristocetin was used.
Perturbation8 causing the u.v. difference 8pectra.
The u.v. difference spectrum induced upon combination of ristocetin B with the standard peptide Ac2-L-Lys-D-Ala-D-Ala (Fig. 1 ) is made ofa negative perturbations resembling each other; thus the shoulder at abott 279nm is induced by L-alanine at position 3 ( Fig. 3) or D-alanine in position 1 (Fig. 2) . Since on structural grounds it is very difficult to imagine that these two side chains interact with the same phenolice group in ristocetin B, it seems probable that they interact in the same way with different phenolic groups having very similar absorption characteristics. In no case are the difference spectra quantitatively additive, again suggesting that the perturbations causing them are not independent, so that to some extent the spectra reflect an interaction with the peptide as a whole. When the side chain at position 3 ( Fig. 4) was varied comparatively few qualitative changes in the near-u.v. difference spectrum were produced, although the presence of a L-tyrosine residue eliminated the negative shoulder at 279nm as well as decreasing the quantitative difference at the minimum at 287nm. Free amino groups decreased the interaction, but altered the shape of the difference spectrum to a surprisingly small extent (Fig. 5) . The explanation of this might be that any electrostatic repulsion leading to a decreased affinity took place with a group on the ristocetin not closely connected to the phenol residues.
Ristocetin A and ristomycin A. Very little is known about the chemistry of the ristocetins. However, a group of Russian workers has recently reported the results of a fairly detailed study on the structure of ristomycin A (Lomakina, Bognar, Brazhnikova, Sztaricskai & Muravyeva, 1970b) . This is an antibiotic isolated from Proactinomyces fructiferi (Gause, Kudrina, Ucholina & Gavrilina, 1963 ) and believed to have a similar chemical composition and mode of action to the ristocetins. A sample of purified ristomycin A was obtained from Professor G. F. Gause. Its ability to combine with Ac2-L-Lys-D-Ala-D-Ala was tested by u.v. difference spectroscopy and optical rotatory dispersion and compared with that of ristocetin A. The optical rotatory dispersion of both antibiotics was identical within experimental error and only minor quantitative differences were evident when the complexes with peptide were compared (Fig. 6) . The u.v. difference spectra developed by the addition of the same peptide were also very similar (Fig. 7) . Since the sugar moieties of ristomycin A and ristocetin A seem to be identical (Lomakina et al. 1968b; Lomakina, Spiridonova, Bognar, Puskas & Sztaricskai, 1968c ) and since we can expect the optical rotatory behaviour in this near-u.v. region of the spectrum to depend mainly on the phenolic chromophores, it seems reasonable to conclude that both antibiotics are identical or nearly identical. Small differences in the spectra of their complexes might be due to unequal purity of the samples. On the other hand, the u. 10-3 X Wave number (cm-') Fig. 3 . Effect of the side chain of residue 3 on the u.v. difference spectrum. U.v. difference spectra of ristocetin B were induced by complex-formation with: (-), Ac-LAla-Gly-Gly; (....), Ac-Gly-Gly-Gly-Gly. Experimental conditions were as in Fig. 1. optical rotatory dispersion and u.v. difference spectra obtained on complex-formation of the ristocetins and vancomycin with peptide are quite different and one would expect the aglycones to be chemically different in some major respects, even if their basic structure is similar.
The aglycones of ristomycin A were prepared by methanolysis (Lomakina et al. 1968b ). The products were separated by t.l.c. into two bands that gave a yellow colour with diazotized sulphanilic acid, one Wavelength (nm) 10-3 X Wave number (cm-1) Fig. 4 . Effect of the side chain of residue 3 on the u.v. difference spectrum. U.v. difference spectra induced on ristooetin B bycomplex-formation with:
Experimental conditions were as in Fig. 1. barely separated from the origin (aglycone 1) and one with RFO.42 (aglycone 2). Samples of the eluted materials were hydrolysed and shown to be free ofsugar residues. Both aglycone 1 addition of peptide had no effect. The final difference spectra (Fig. 8 ) may be compared with that of ristomycin A (Fig. 7) . The difference spectrum of aglycone 1 retained the minima at 286nm and in the far u.v., but the shoulder at 294nm had disappeared and was replaced by a maximum at the same wavelength. This resembles the difference spectrum of vancomycin induced by combination with the same peptide (Nieto & Perkins, 1971b) . The difference spectrum of aglycone 2 was relatively featureless, although once more a large negative difference developed in the far u.v. By assuming that aglycone 1 had E"yo at 278nm of 64 (Lomakina et al. 1968b) , the difference spectra were used to calculate the equivalent weight of combination with the peptide (Nieto & Perkins, 1971a) . The resulting value of 1300 agrees fairly well with that of 1500 calculated from the specific absorption of the NNdiDNP derivatives by the Russian authors. The antibiotic action of the aglycones was tested against Micrococeu8 ly8odeiktwes by the hole-inplate method (Perkins, 1969) . Concentrations of 50,g/ml (calculated from E278 as above) were placed in the wells and the zones of no growth were compared with that given by ristomycin A. The diameters were as follows: ristomycin A, 17 mm; aglycone 1, 16mm; aglycone 2, 13.5mm. Evidently both aglycones were antibiotics, as expected from their ability to complex with the specific peptide.
DISCUSSION
Complex-formation between ristocetin B and specific peptides. The general model for complex-formation with ristocetin would be the same as that for vancomycin (Nieto & Perkins, 1971b) 'cleft' holding the peptide would be wider around residue 1 and narrower around residue 2 of the peptide, whereas the reverse is true for vancomycin. A similar contribution to AG is made by the peptide backbone for both antibiotics, but for ristocetin increasing the size of the side chain of residue 1 of the peptide from a methylfto anPisobutyl group had no effect on the affinity, whereas combination with vancomycin was adversely affected. These facts support the idea that one of the main interactions contributing to the binding with either antibiotic is a polar bond (ionic or hydrogen bond) between the carboxyl group of the peptide and an amino or hydroxyl group of the antibiotic in a hydrophobic environment in the complex. This bond would be insulated from the solvent by the peptide side chains and the effectiveness of this insulation would depend on the length ofthe peptide and the size of the side chains in relation to the precise geometry of the antibiotic.
Aglycone8 of ritomycin A. Ristomycin A combined with AC2-L-Lys-D-Ala-D-Ala in a way similar to that of ristocetin. When the sugar residues were removed chemically to yield aglycones, these products were antibiotically active and also combined with peptide. Molecular models of the aglycone that were constructed to fit the incomplete structural data of Lomakina et al. (1968a; 1970b) only showed that it was possible to build a 'phenolic cleft' having the correct size to accept residues 1 and 2 of the peptide as postulated by Nieto & Perkins (1971b) . However, there was no obvious manner of fitting the peptide Ac-D-Ala-D-Ala into the cleft in a way that was consistent with the known specificity of complex-formation. Many hydrogen-bond interactions were possible but none of them seemed to coincide with an optimum geometrical 'fit'. Hence, more details about the structure of the complexes will have to await confirnation of the structure of the aglycone and, perhaps, X-ray-crystallographic studies.
Interaction of ristocetin B with bacteria cell wa1l8. In addition to binding nearly as well as vancomycin to D-Ala-D-Ala termini, ristocetin will bind much more strongly to the mucopeptide crossbridges of bacteria of the chemotypes I and IV defined by Ghuysen (1968) . M. ly8odeikticu4s mucopeptide, on the other hand, contain D-Glu-Gly sequences and therefore should combine firmly with vancomycin but only very weakly with ristocetin B (Table 1) . Sinha & Neuhaus (1968) reported reversal of the inhibition caused by vancomycin and ristocetin in a M. ly8odeikticuB cell-free system that synthesizes mucopeptide, by cell walls from the same microorganism. However, reversal did not occur to the same extent for both antibiotics: under conditions in which it was virtually complete for vancomycin, M. ly8odeikticu cell walls achieved only about 30% reversal of the inhibition by ristocetin. This may be accounted for by the very low affinity of ristocetin for peptides ending in D-Glu-Gly, when compared with their affinity for vancomycin. Under the conditions in which the biosynthetic assay was carried out M. Zy8odeikticu8 cell walls adsorbed both antibiotics from solution. However, the amount of cell walls required for half-maximal adsorption of 1.0mg of antibiotic from solution was 0.68mg for vancomycin and 4.88mg for ristocetin (Sinha & Neuhaus, 1968) . This difference in affinity is completely consistent with the above explanation. One could predict on these grounds that cell walls from C. poinsettiae, for instance, would be more effective in the reversal of inhibition by ristocetin than by vancomycin and that Staphylococcuf8 aureuh cell walls would be equally good for both antibiotics. Sinha & Neuhaus (1968) also reported a 50% inhibition of mucopeptide synthesis in the M. ly8odeikticwu biosynthetic system by 7.5,&g/ml ofristocetin compared with 20 ,g/ml ofvancomycin.
This could be explained if in the preformed mucopeptide chains assumed to be the acceptors for the addition of new disaccharide-pentapeptide units there were D-Glu-Gly chains present. These chains would bind some of the vancomycin, which would thus become unavailable for inhibitory action, whereas binding of ristocetin by these peptide chains would be very weak.
